All Oncology News

Claud N. Grigg, MD, highlights different frontline combination regimens that are improving outcomes for patients with metastatic renal cell carcinoma.

A recent wave of drug approvals for treating prostate cancer in earlier disease states, coupled with genomic advances, may help pave the way for a shift toward handling the malignancy as a chronic condition.

AstraZeneca has voluntarily withdrawn durvalumab from the US market for the treatment of adult patients with locally advanced or metastatic bladder cancer.

Davey B. Daniel, MD, discusses key immunotherapy trials in advanced non–small cell lung cancer and explains how the results can be extrapolated to clinical practice.

Although chemotherapy remains the cornerstone of treatment in pancreatic ductal adenocarcinoma, the field has begun to carve out more personalized approaches evidenced by the POLO trial.

When one is dealing with the topic of cancer, its treatment and consequences, language that clinicians and members of the cancer research community use may have an even greater impact.

February 19, 2021 - The National Comprehensive Cancer Network has issued guidelines for the management of children with a rare type of kidney cancer referred to as Wilms Tumor, or nephroblastoma.

February 19, 2021 - Multitarget stool DNA test Cologuard could present a potential noninvasive screening method for colorectal cancer, as it has demonstrated high specificity among average-risk patients aged 45 to 49 years.

Patients with metastatic renal cell carcinoma have a new frontline treatment alternative following FDA approval of the combination of nivolumab plus cabozantinib combination.

Christos Vaklavas, MD, discusses the progress that has been made in metastatic HR-positive, HER2-negative breast cancer and potential pathways forward for therapeutic sequencing.

A reduced frequency of maintenance vincristine and dexamethasone led to a 5-year overall survival rate of 98.6% and improved quality of life in pediatric patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia.

Reema A. Patel, MD, discusses the potential for nanoliposomal irinotecan in pancreatic cancer and other emerging approaches under exploration.

Kanwarpal S. Kahlon, MD, discusses the nuances of approaching treatment in ITP, updated guidelines to inform treatment selection, and recent data presented during the 2020 ASH Annual Meeting and Exposition that have the potential to advance the field.

Parameswaran Hari, MD, MRCP, discusses single-agent and combination strategies that have recently been introduced to the relapsed/refractory multiple myeloma setting and the nuances to utilizing them in clinical practice.

February 18, 2021 - One hundred and thirty organizations, cancer centers, and other institutions sent a letter to President Joe Biden and his administration, as well as other leading public health officials at state health departments to underscore the need to provide patients with cancer and survivors of cancer with priority access to a coronavirus disease 2019 vaccine.

Kabir Mody, MD discusses new directions with yttrium-90 glass microspheres in hepatocellular carcinoma as demonstrated in the retrospective LEGACY study.

February 18, 2021 - Single-agent cemiplimab has been found to result in a significant improvement in overall survival and progression-free survival versus chemotherapy in patients with advanced non–small cell lung cancer who had a PD-L1 expression of at least 50%.

Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.

Yi Lin, MD, PhD, discusses promising data with CAR T-cell therapy in multiple myeloma.

February 18, 2021 - Two supplemental biologics license applications have been submitted to the FDA for enfortumab vedotin-ejfv to convert the agent’s accelerated approval into a regular one and to expand the current label to include patients with locally advanced or metastatic urothelial cancer who had received prior treatment with a PD-1/PD-L1 inhibitor and are not eligible for cisplatin.

February 18, 2021 — The use of next-generation sequencing demonstrated that 34% of patients with sarcoma had potentially actionable mutations.

The identification of oncogenic driver mutations in non–small cell lung cancer to inform targeted therapy selection is the bedrock of clinical practice in this disease, with current estimates suggesting that more than half of patients harbor an actionable mutation.

Rafael Fonseca, MD, discusses several clinical trials that support the use of quadruplet regimens in myeloma, the utilization of MRD in clinical decision-making, and future directions for research.

Marc J. Braunstein, MD, PhD, discusses the evolution and promise of immunotherapeutics in multiple myeloma.

Parameswaran Hari, MD, MRCP, discusses the efficacy of combination carfilzomib, pomalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma.

Kristen K. Ciombor, MD, MSCI, discusses responses achieved with preoperative chemoradiation in patients with rectal cancer.

February 17, 2021 - An independent data monitoring committee has concluded that the phase 3 OlympiA trial examining olaparib crossed the superiority boundary for its primary end point of invasive disease-free survival in patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer.

February 17, 2021 - The FDA has accepted and granted a priority review designation to the biologics license application for Vicineum for use in patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.

February 17, 2021 - Carl H. June, MD, and Steven A. Rosenberg, MD, PhD, have received the 2021 Dan David Prize Laureate for their research in oncology. They, along with Zelig Eshhar, an immunologist at the Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center, will share a prize of $1 million.

The first patient with operable, locally or regionally advanced melanoma has been dosed with the intratumoral DNA plasmid-based interleukin-12 therapy tavokinogene telseplasmid in combination with nivolumab as a neoadjuvant treatment before surgery in the investigator-initiated, phase 2 OMS-104 trial.